Connect your AI

Janus Living JAN Sale Of Stock Placement Agent Fee Allocable Portion

Sale Of Stock Placement Agent Fee Allocable Portion at other companies

Navitas Semiconductor CorporationNVTS

$1.11M—

QuantumScape Corporation QS

$101K-85.7%

Starwood Property TrustSTWD

$1.74M-72.6%

Medline, Inc. MDLN

$3M—

Equity Lifestyle PropertiesELS

$70K+14.8%

Mirum Pharmaceuticals, Inc.MIRM

$259.95M—

Other financials

Income statement

Revenue$4.7M-2.8%

Gross profit$3.6M+85.6%

Operating income-$2.7M-41.0%

Net income-$271.5M-11,250%

EPS (diluted)-$2.14-1,327%

Balance sheet

Cash & equivalents$10.5M-2.7%

Total debt$107.0K-99.4%

Total equity$889.7M+3,976%

Total assets$959.7M+1,130%

Cash flow

Operating cash flow-$12.3M-764%

CapEx$2.8K—

Free cash flow-$1.8M—

Valuation

Market cap$5.56B+43,568%

Enterprise value$5.55B+26,232%

P/S231.5×+231×

Profitability

Gross margin46.5%+1.2pp

Operating margin-99.7%-717pp

Net margin-2,552.7%-2,601pp

FCF margin-29.7%—

Returns & leverage

Return on equity-134.6%-791pp

Debt / equity0×-0.5×

Current ratio0.8×0.0×

Where this comes from

Reported directly by Janus Living in its filing.

Tagged under the XBRL concept ALTS:SaleOfStockPlacementAgentFeeAllocablePortion.

The official record: Janus Living ’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janus Living 's sale of stock placement agent fee allocable portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Janus Living 's sale of stock placement agent fee allocable portion?: Janus Living (JAN) reported sale of stock placement agent fee allocable portion of 50% in Q3 2025.
What does sale of stock placement agent fee allocable portion mean?: This represents the portion of fees paid to financial intermediaries or placement agents specifically allocated to the issuance of equity securities. It reflects the cost of capital acquisition through private or public stock offerings. Tracking this helps evaluate the efficiency and cost-effectiveness of the company's equity financing activities.